Antral Follicle Priming Prior to ICSI (Intracytoplasmic Sperm Injection) in Previously Diagnosed Low Responders

• Status: Completed
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is to compare the effectiveness of testosterone,estradiol and a combined treatment with estrogens/progestagens prior to IVF-ICSI in previously diagnosed low responder patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto de Investigacion Sanitaria La Fe
• Treatments: Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Ethinyl Estradiol; Methyltestosterone; Polyestradiol phosphate; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate

Criteria

Inclusion Criteria:

1. Phase 1 (Non randomized. The patient must fit the first plus at least other 2 criteria)

• Infertility requiring an IVF/ICSI treatment

• Age ≥ 38 years

• Basal FSH ≥ 10 mUI/ml (day 3 of the cycle)

• Serum AMH ≤ 5 pmol/l

• Antral follicular count ≤ 6 (day 3 of the cycle)

2. Phase 2 (Randomized. The patient must fit at least one criterion regarding the day of GNRH analogue administration during the cycle performed in Phase 1)

• Less than 4 follicles which mean diameter measuring more than 16mm

• Serum estradiol levels ≤ 500 pg/ml

• 4 MII or less than 4 MII oocytes retrieved

Exclusion Criteria:

• Patients suffering of endometriosis

• Patients having progesterone levels ≤ 4 ng/ml (day 21 of the cycle)

• Patients having a partner affected by severe oligo/astheno/teratozoospermia